FDA Fast-Tracks Verastem’s Breakthrough Oral Drug for KRAS G12D Lung Cancer
Verastem’s VS-7375 pill targets KRAS G12D lung cancer, a rare, hard-to-treat mutation with no approved drugs yet.
/ 1653 items
#XY↓
Mineralys Therapeutics Raises $650M+ in Capital Blitz to Clear Path for Lorundrostat Launch
Mineralys raised cash via $150M stock sale, $500M loan, and $200M royalty buyout to fund drug ahead of FDA decision; stock fell.
Briumvi’s New Subcutaneous Formulation Boosts TG Therapeutics Stock
TG Therapeutics stock rose after early trial results showed its under-skin MS drug worked well and may allow at-home dosing.
Jefferies Bullish on ACHC: New Management to Drive Stability and Higher Profits
Jefferies upgraded ACHC to Buy, raised target to $30, citing better management, stability, and profit upside after strong gains.
Wall Street Upgrades Rezolute After Strong Phase 3 Trial Results in Tumor Hyperinsulinism
Rezolute’s drug showed strong Phase 3 results, reducing IV glucose needs in rare tumor HI. Analysts raised targets and turned bullish.
Medline Shares Tumble After FDA Slams Repeated Bacteria Contamination at Illinois Plant
FDA warned Medline over contamination issues at Illinois plant. Stock fell. Company must fix cleaning and safety problems quickly.